SMART-102

N/A

Report date: 2022/11/20 14:41:33

Base Information

Drug NameSMART-102
Drug Alias NameAllogeneic T-cell progenitors（Smart Immune）SMART-102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSmart Immune SAS
China Registration ClassN/A

Develop Information

Active CompaniesAssistance Publique Hopitaux De ParisSmart Immune SAS
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A